



UNITED STATES PATENT AND TRADEMARK OFFICE





UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/830,780	05/01/2001	Thomas Hille	512100-2010	3693	
20999	7590 02/11/2004		EXAMI	EXAMINER	
FROMMER LAWRENCE & HAUG			MENDEZ, MANUEL A		
745 FIFTH A NEW YORK,	VENUE- 10TH FL. , NY 10151		ART UNIT	PAPER NUMBER	
,	,		3763	-	
			DATE MAILED: 02/11/2004	1	

Please find below and/or attached an Office communication concerning this application or proceeding.

	<u>**</u>		ے			
	Application No.	Applicant(s)				
•	09/830,780	HILLE ET AL.				
Office Action Summary	Examiner	Art Unit				
	Manuel Mendez	3763				
The MAILING DATE of this communication apperiod for Reply	pears on the cover sheet with	the correspondence addre	ss			
A SHORTENED STATUTORY PERIOD FOR REPL THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a repl - If NO period for reply is specified above, the maximum statutory period - Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailin earned patent term adjustment. See 37 CFR 1.704(b).	136(a). In no event, however, may a repl ly within the statutory minimum of thirty (will apply and will expire SIX (6) MONTH e, cause the application to become ABAN	y be timely filed 30) days will be considered timely. S from the mailing date of this comm IDONED (35 U.S.C. § 133).	unication.			
Status						
1) Responsive to communication(s) filed on						
· · · · · · · · · · · · · · · · · · ·	—· s action is non-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is						
closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
4) ⊠ Claim(s) <u>1-50</u> is/are pending in the application 4a) Of the above claim(s) is/are withdra 5) □ Claim(s) is/are allowed. 6) □ Claim(s) is/are rejected. 7) □ Claim(s) is/are objected to. 8) ⊠ Claim(s) <u>1-50</u> are subject to restriction and/or	own from consideration.					
Application Papers						
9) The specification is objected to by the Examina 10) The drawing(s) filed on is/are: a) accomposite and accomposite accomposite and accomposite and accomposite and accomposite accomposite and accomposite and accomposite accomposi	cepted or b) objected to by drawing(s) be held in abeyance ction is required if the drawing(s)	e. See 37 CFR 1.85(a). is objected to. See 37 CFR				
	Adminor. Note the attached t					
Priority under 35 U.S.C. § 119 12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority document application from the International Bureat * See the attached detailed Office action for a list	ts have been received. ts have been received in Apporty documents have been re nu (PCT Rule 17.2(a)).	olication No eceived in this National Sta	age			
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	Paper No(s)/l	nmary (PTO-413) Mail Date rmal Patent Application (PTO-15	i2)			

Application/Control Number: 09/830,780

Art Unit: 3763

DETAILED ACTION

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- Claims 1-18, drawn to the use of a transdermally administrable active compound having a low skin penetration rate, classified in class 601, subclass 2.
- II. Claims 19-37, drawn to a process for the administration of a transdermally administrable active compound having a low skin penetration rate, classified in class 604, subclass 501.
- III. Claims 38-49, drawn to a device for transdermal therapy, classified in class 604, subclass 22.
- IV. Claim 50, drawn to the use of ultrasound for increasing the skin penetration rate of a transdermally administratable active compound in a process for transdermal therapy, classified in class 128, subclass 673.

The inventions are distinct, each from the other because of the following reasons:

Inventions I, II, III and IV are related as subcombinations disclosed as usable together in a single combination. The subcombinations are distinct from each other if they are shown to be separately usable. In the instant case, inventions I, II, III, and IV have separate utility. See MPEP § 806.05(d).

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.

Application/Control Number: 09/830,780

Art Unit: 3763

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Manuel Mendez whose telephone number is 703-308-2221. The examiner can normally be reached on 0730-1800 hrs.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mr. Brian Casler can be reached on 703-308-3552. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Manuel Mendez Primary Examiner Art Unit 3763

MM